HUP0300378A2 - Oxazolidinontartalmú tablettakészítmények és előállításuk - Google Patents

Oxazolidinontartalmú tablettakészítmények és előállításuk

Info

Publication number
HUP0300378A2
HUP0300378A2 HU0300378A HUP0300378A HUP0300378A2 HU P0300378 A2 HUP0300378 A2 HU P0300378A2 HU 0300378 A HU0300378 A HU 0300378A HU P0300378 A HUP0300378 A HU P0300378A HU P0300378 A2 HUP0300378 A2 HU P0300378A2
Authority
HU
Hungary
Prior art keywords
oxazolidinone
cellulose
stearic acid
starch
hydroxypropyl
Prior art date
Application number
HU0300378A
Other languages
English (en)
Inventor
Homer Lin
Ken Yamamoto
Original Assignee
Pharmacia & Upjohn Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0300378(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co. filed Critical Pharmacia & Upjohn Co.
Publication of HUP0300378A2 publication Critical patent/HUP0300378A2/hu
Publication of HUP0300378A3 publication Critical patent/HUP0300378A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A találmány tárgya préselt tabletta, amely magas vér-hatóanyagszintetnyújt és jó biológiai hozzáférhetőségű, és amelynek összetevői:antibakteriális hatású oxazolidinon, keményítő, mikrokristályoscellulóz, kötőanyag, amely lehet hidroxipropilcellulóz,hidroxipropilmetilcellulóz, povidon és/vagy kukoricakeményítő-pép,szétesést elősegítő szerek, amelyek lehetnek nátriumkeményítő-glikolát, kroszkarmellóz-nátrium, kroszpovidon és/vagy kishelyettesítettségű hidroxipropilcellulóz és csúszást elősegítő szerek,amelyek lehetnek sztearinsav, sztearinsav fémsói, hidrogénezettnövényi olajok és/vagy talkum. A találmány tárgyát képezi továbbáantibakteriális hatású oxazolidinon, keményítő, mikrokristályoscellulóz, kötőanyag, amely lehet hidroxipropilcellulóz,hidroxipropilmetilcellulóz, povidon és/vagy kukoricakeményítő-pép,szétesést elősegítő szerek, amelyek lehetnek nátriumkeményítő-glikolát, kroszkarmellóz-nátrium, kroszpovidon és/vagy kishelyettesítettségű hidroxipropilcellulóz és csúszást elősegítő szerek,amelyek lehetnek sztearinsav, sztearinsav fémsói, hidrogénezettnövényi olajok és/vagy talkum alkalmazása olyan préselttablettaformájú gyógyászati készítmény előállítására, amely orálisadagolás esetén az antibakteriális oxazolidinon olyan vérszintjétbiztosítja, amely gyógyászatilag ekvivalens az azonos antibakteriálisoxazolidinon intravénás adagolásakor elért vérszinttel. Ó
HU0300378A 2000-03-22 2001-03-15 Oxazolidinone tablet formulation and their preparation HUP0300378A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19096900P 2000-03-22 2000-03-22
PCT/US2001/005812 WO2001070225A2 (en) 2000-03-22 2001-03-15 Oxazolidinone tablet formulation

Publications (2)

Publication Number Publication Date
HUP0300378A2 true HUP0300378A2 (hu) 2003-06-28
HUP0300378A3 HUP0300378A3 (en) 2004-11-29

Family

ID=22703542

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300378A HUP0300378A3 (en) 2000-03-22 2001-03-15 Oxazolidinone tablet formulation and their preparation

Country Status (33)

Country Link
EP (1) EP1265608B1 (hu)
JP (1) JP2003527424A (hu)
KR (2) KR20070094673A (hu)
CN (1) CN1208058C (hu)
AR (1) AR033357A1 (hu)
AT (1) ATE412413T1 (hu)
AU (2) AU4324301A (hu)
BG (1) BG107117A (hu)
BR (1) BR0108846A (hu)
CA (1) CA2400118A1 (hu)
CZ (1) CZ20023133A3 (hu)
DE (1) DE60136341D1 (hu)
DK (1) DK1265608T3 (hu)
EA (1) EA006772B1 (hu)
EC (1) ECSP013979A (hu)
ES (1) ES2312422T3 (hu)
HK (1) HK1054325B (hu)
HR (1) HRP20020765A2 (hu)
HU (1) HUP0300378A3 (hu)
IL (1) IL151788A0 (hu)
MX (1) MXPA02009316A (hu)
MY (1) MY136370A (hu)
NO (1) NO20024505L (hu)
NZ (1) NZ521525A (hu)
PE (2) PE20011126A1 (hu)
PL (1) PL201686B1 (hu)
PT (1) PT1265608E (hu)
SK (1) SK12092002A3 (hu)
TW (1) TWI293028B (hu)
UA (1) UA77654C2 (hu)
WO (1) WO2001070225A2 (hu)
YU (1) YU69802A (hu)
ZA (1) ZA200207073B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
ES2309920T3 (es) * 2005-07-20 2008-12-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica estable que comprende la forma iii de linezolid.
WO2010026597A1 (en) * 2008-09-02 2010-03-11 Hetero Research Foundation Oral dosage forms of linezolid and processes for their preparation
ES2836809T3 (es) * 2010-11-24 2021-06-28 Melinta Subsidiary Corp Composiciones farmacéuticas
WO2013088389A1 (en) * 2011-12-14 2013-06-20 Alembic Pharmaceuticals Limited Linezolid premix
CN103505459B (zh) * 2012-06-20 2016-02-24 北京万生药业有限责任公司 利奈唑胺药物组合物
CN104622831B (zh) * 2013-11-06 2018-06-22 江苏豪森药业集团有限公司 一种口服片剂及其制备方法
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
CN106727396A (zh) * 2016-11-22 2017-05-31 湖北广济药业股份有限公司 一种ⅱ晶型利奈唑胺片及其制备方法
CN109481412A (zh) * 2018-08-17 2019-03-19 扬子江药业集团北京海燕药业有限公司 一种ii晶型利奈唑胺片及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993767A (en) * 1975-11-18 1976-11-23 A. H. Robins Company, Incorporated Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
AU767380B2 (en) * 1999-05-27 2003-11-06 Pharmacia & Upjohn Company Bicyclic oxazolidinones as antibacterial agent

Also Published As

Publication number Publication date
UA77654C2 (en) 2007-01-15
AU2001243243B2 (en) 2004-10-14
ES2312422T3 (es) 2009-03-01
AU4324301A (en) 2001-10-03
CN1208058C (zh) 2005-06-29
CZ20023133A3 (cs) 2003-01-15
DE60136341D1 (de) 2008-12-11
HUP0300378A3 (en) 2004-11-29
EP1265608B1 (en) 2008-10-29
NZ521525A (en) 2004-02-27
WO2001070225A3 (en) 2001-12-13
PE20011126A1 (es) 2001-10-31
JP2003527424A (ja) 2003-09-16
ZA200207073B (en) 2003-12-03
TWI293028B (en) 2008-02-01
HRP20020765A2 (en) 2003-12-31
CA2400118A1 (en) 2001-09-27
ATE412413T1 (de) 2008-11-15
NO20024505D0 (no) 2002-09-20
KR20020083185A (ko) 2002-11-01
SK12092002A3 (sk) 2002-12-03
AR033357A1 (es) 2003-12-17
MXPA02009316A (es) 2004-04-05
PL201686B1 (pl) 2009-04-30
MY136370A (en) 2008-09-30
CN1418097A (zh) 2003-05-14
EA006772B1 (ru) 2006-04-28
HK1054325B (zh) 2006-01-13
BR0108846A (pt) 2003-05-06
EA200201006A1 (ru) 2003-02-27
WO2001070225A2 (en) 2001-09-27
KR100786410B1 (ko) 2007-12-17
KR20070094673A (ko) 2007-09-20
ECSP013979A (es) 2002-01-25
HK1054325A1 (en) 2003-11-28
EP1265608A2 (en) 2002-12-18
DK1265608T3 (da) 2008-12-08
NO20024505L (no) 2002-09-20
PT1265608E (pt) 2008-12-15
IL151788A0 (en) 2003-04-10
PE20020499Z (es) 2002-07-12
BG107117A (bg) 2003-05-30
YU69802A (sh) 2005-11-28
PL366067A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
CA2607098C (en) Dispersible bosentan tablet
ES2333206T3 (es) Combinacion de inhibidores de la proteasa dependiente del citocromo p450.
RU2010128019A (ru) Пероральная диспергируемая таблетка
SG10201407947WA (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
HUP0401978A2 (hu) Tamszulozintabletták
JP2006516570A5 (hu)
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
HUP0300378A2 (hu) Oxazolidinontartalmú tablettakészítmények és előállításuk
AR088319A1 (es) Comprimido que comprende 7-[4-(4-benzo[b]tiofen-4-il-piperacin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales
NO332190B1 (no) Enterisk belagt pyridoksin HCl- og doksylaminsuksinat-preparat med rask virkningsinntreden, anvendelse derav, medikament og fremgangsmate for fremstilling av preparatet.
CR10668A (es) Comprimidos pediatricos de capecitabina
WO2010069795A3 (en) Capecitabine rapidly disintegrating tablets
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
RU2006137329A (ru) Распадающиеся таблетки, содержащие ликарбазепин
KR102286386B1 (ko) 아타자나비르 및 코비시스타트의 ｈｉｖ 치료 제제
WO2023109978A3 (zh) 桑提取物在制备治疗胰腺相关疾病的药物中的应用
KR101869127B1 (ko) 테가푸르, 기메라실 및 오테라실칼륨 함유 구강내 붕괴정
JP2019011322A (ja) 医薬組成物
US20080234285A1 (en) Combination of Organic Compounds
KR102431738B1 (ko) 초고속 붕해 정제 및 그 제조 방법
US20050256131A1 (en) Pharmaceutical active substance combination and the use thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees